RxDoctor Payments Data

Elsa Reyes, MD

Internal Medicine · New York, NYNPI 1184783243

Payments from drug & device makers

$773in general payments, 2019–2025

Across 35 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$133
  • Amarin Pharma, Inc.$103
  • Lilly USA, LLC$98
  • Ardelyx, Inc.$84
  • Boehringer Ingelheim$77
  • GSK$68
  • plus $211 from 7 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$773 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,787
Medicare patients
14
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$85,204
JanuviaSitagliptin Phosphate70$53,466
JardianceEmpagliflozin53$43,350
VascepaIcosapent Ethyl122$42,704
TrulicityDulaglutide30$41,393
JanumetSitagliptin Phos/Metformin Hcl44$33,782
FarxigaDapagliflozin Propanediol52$33,436
LinzessLinaclotide34$19,617
EliquisApixaban30$18,474
EntrestoSacubitril/Valsartan20$17,830
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$15,300
XareltoRivaroxaban20$12,710
Incruse ElliptaUmeclidinium Bromide27$8,987
MyrbetriqMirabegron15$6,836
Spiriva RespimatTiotropium Bromide12$6,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$85,20490 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$77$55,51477 claims
Lilly USA, LLCTrulicity$98$41,39330 claims
NovartisEntresto$48$17,83020 claims
GSKIncruse Ellipta, Arnuity Ellipta$68$12,94647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →